tiprankstipranks
Kiniksa Pharmaceuticals Reports Strong ARCALYST Growth
PremiumCompany AnnouncementsKiniksa Pharmaceuticals Reports Strong ARCALYST Growth
1M ago
Kiniksa Pharmaceuticals Ends License Agreement with MedImmune
Premium
Company Announcements
Kiniksa Pharmaceuticals Ends License Agreement with MedImmune
1M ago
Kiniksa reports Q4 EPS (12c), consensus 13c
Premium
The Fly
Kiniksa reports Q4 EPS (12c), consensus 13c
1M ago
Kiniksa reports preliminary Q4 ARCALYST net product revenue $121.9M
PremiumThe FlyKiniksa reports preliminary Q4 ARCALYST net product revenue $121.9M
2M ago
Short Report: CompoSecure shorts at multi-month lows
Premium
The Fly
Short Report: CompoSecure shorts at multi-month lows
3M ago
Kiniksa Pharmaceuticals (KNSA) Stock Drops 17%, Presenting a Potential Opportunity
Premium
Market News
Kiniksa Pharmaceuticals (KNSA) Stock Drops 17%, Presenting a Potential Opportunity
5M ago
Kiniksa sees FY24 ARCALYST revenue between $410M-$420M
PremiumThe FlyKiniksa sees FY24 ARCALYST revenue between $410M-$420M
5M ago
Kiniksa reports Q3 EPS (18c), consensus 3c
Premium
The Fly
Kiniksa reports Q3 EPS (18c), consensus 3c
5M ago
Kiniksa partners with Carly Pearce in expansion of Life DisRPted campaign
Premium
The Fly
Kiniksa partners with Carly Pearce in expansion of Life DisRPted campaign
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100